{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000034","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.871303+00:00","generated_at":"2026-06-01T04:33:46.482976+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination","bullets":["Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.","Plamotamab is Phase 2 ready, having completed Phase 1 enrollment in hematologic cancers in late 2023.","Janssen retains rights to develop B-cell targeting CD28 bispecifics, including JNJ-9401 and JNJ-1493, now in Phase 1.","Two collaboration agreements with Janssen continue; Xencor remains eligible for milestones and royalties on retained CD28 programs.","Xencor has opt-in rights to co-fund development of JNJ-9401 (20%) and JNJ-1493 (15%) upon proof-of-concept."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000034","json":"https://secwatch.observer/filing/0001326732-24-000034.json","markdown":"https://secwatch.observer/filing/0001326732-24-000034.md","text":"https://secwatch.observer/filing/0001326732-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/0001326732-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/xncr-20240613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:33:46.482976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}